Contents

Search

asenapine (Saphris)

Indications: - schizophrenia - depression, bipolar disorder, mania - psychosis & agitation in the elderly [3] Dosage: - 5-10 mg sublingual - transdermal system FDA-approved Oct 2019 Adverse effects: - severe allergic reactions, anaphylaxis [2] - sedation - black box warning [3] - increased risk of hyperglycemia - increased risk of cerebrovascular events - increased risk of mortality in patients with dementia Notes: - cost: $478/month, 10 mg QD (2009)

Interactions

drug adverse effects of antipsychotic agents monitor with atypical antipsychotic agents

General

atypical antipsychotic agent; second generation antipsychotic

References

  1. Prescriber's Letter 16(10): 2009 Comparison of Atypical Antipsychotics Detail-Document#: 251010 (subscription needed) http://www.prescribersletter.com
  2. FDA MedWatch 09/01/11 Saphris (asenapine maleate): Drug Safety Communication: Serious Allergic Reactions http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm270600.htm - Prescriber's Letter 18(10): 2011 Saphris (Asenapine) and Serious Allergic Reactions Detail-Document#: 271008 (subscription needed) http://www.prescribersletter.com
  3. Geriatric Review Syllabus, 8th edition (GRS8) Durso SC and Sullivan GN (eds) American Geriatrics Society, 2013
  4. U.S. FDA Approves SECUADO (asenapine) Transdermal System, the First-and-Only Transdermal Patch for the Treatment of Adults with Schizophrenia. Business Wire. Oct 15, 2019 https://www.businesswire.com/news/home/20191015005668/en/U.S.-FDA-Approves-SECUADO%C2%AE-asenapine-Transdermal-System